drugset / Trial / NCT03785106
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
Phase 3
Active not recruiting
2500 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Bhumibol Adulyadej Hospital · collabBuddhachinnaraj Hospital · collabChiangrai Prachanukroh Hospital · collabHatYai Hospital · collabKing Chulalongkorn Memorial Hospital · collabKlang Hospital · collabMaharat Nakhon Ratchasima Hospital · collabPolice General Hospital · collabPranangklao Hospital · collabQueen Sawang Vadhana Memorial Hospital · collabSanpatong Hospital · collabSisaket Hospital · collabSrinagarind Hospital, Khon Kaen University · collabTaksin Hospital · collabThe Public Health Centre 28 Krung thon buri · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the prevention of TB in human immunodeficiency virus (HIV)-infected individuals.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2038-03
- Completion
- 2038-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isoniazid | Small molecule | — | — |
| Subject | Rifapentine | Small molecule | — | — |
| Background | Pyridoxine | Unknown | — | — |
Indications
No indication recorded.